© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Pyxis Oncology, Inc. (PYXS) shows an Average True Range (ATR) of 0.35 and an Enterprise Value of 268.89M. Its average trading volume over the past 3 months is 969.16K, indicating liquidity. These fundamental metrics provide insight into PYXS's underlying financial health and market activity.
Pyxis Oncology, Inc. (PYXS) technical indicators as of January 1, 2026: the SMA 20 is -59.65%, SMA 50 at -68.52%, and SMA 200 at -42.32%. The RSI 14 value is 22.21, suggesting its current momentum. These technical analysis signals help assess PYXS's price trends and potential future movements.
Pyxis Oncology, Inc. (PYXS) stock performance overview as of January 1, 2026: The 52-week high is $5.55 (currently -79.28% below), and the 52-week low is $0.833 (currently 38.02% above). Over the past year, PYXS's performance is -28.13%, compared to the S&P 500's 12.29% change.
According to market data, Pyxis Oncology, Inc. (PYXS) stock's recent performance metrics show that over the last month, PYXS is -77.84%, with a Year-to-Date (YTD) performance of -26.28%. Over the past year, the stock has seen a -28.13% change. These figures summarize PYXS's price movements across various periods, reflecting its historical returns.
According to current financial data, PYXS stock's P/E (TTM) ratio is -0.75, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for PYXS, including P/S (11.61), P/B (1.06), and P/FCF (-1.00), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.